'Trusted' NHS must bring R&D benefits to the disadvantaged
By and 
James O’Shaughnessy2022-12-14T12:42:00
Realignment of R&D investment could generate a better return on R&D investment to UK plc by improving access to innovative medicines, reducing variations in health outcomes, reengaging people with the labour market, and improving healthy life expectancy, write Jonathan Pearson-Stuttard and James O’Shaughnessy.
Register with hsj.co.uk to read the rest of this article
Critical stories remain free for registered users
Certain articles and Insight pieces remain paying-subscriber only content
As a registered user you will get access to:
- Daily News: an essential email round-up of all the latest news, comment and best practice
- Breaking news headlines delivered directly to your inbox
- Limited access to hsj.co.uk
Already registered to HSJ? Sign in now